MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Medtronic plc
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026
$92.77−1.98 (-2.09%)
Close on Oct 19, 2026
- Market cap
- $119.22B
- P/E (TTM)
- 22.8
- Dividend yield
- 3.06%
Medtronic plc revenue by segment
By business segment
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable segment net sales | $8.88B | $6.66B | $8.99B | $8.93B | $7.79B | $6.14B | $8.26B | $8.37B | $7.97B | $6.04B | $8.04B | $7.92B | 91.1% | +14.1% |
| Cardiovascular | $3.93B | $3.80B | $3.46B | $3.44B | $3.29B | $3.34B | $3.04B | $3.10B | $3.01B | $3.13B | $2.93B | $2.92B | 40.3% | +19.5% |
| Neuroscience | $2.68B | $2.75B | $2.56B | $2.56B | $2.43B | $2.62B | $2.46B | $2.45B | $2.32B | $2.55B | $2.36B | $2.29B | 27.4% | +10.3% |
| Medical Surgical | $2.28B | $2.39B | $2.17B | $2.17B | $2.07B | $2.21B | $2.07B | $2.13B | $2.00B | $2.20B | $2.11B | $2.10B | 23.4% | +9.9% |
| Other Operating Segments, Including Diabetes | $872.00M | – | – | – | $755.00M | – | – | – | – | – | – | – | 8.9% | +15.5% |
| Diabetes | $843.00M | $838.00M | $796.00M | $757.00M | $721.00M | $728.00M | $694.00M | $686.00M | $647.00M | $659.00M | $640.00M | $610.00M | 8.6% | +16.9% |
| Other operating segment, misc | $29.00M | – | – | – | $33.00M | – | – | – | – | – | – | – | 0.3% | -12.1% |
| Other Operating Segments | – | – | $32.00M | $35.00M | $33.00M | $31.00M | $32.00M | $37.00M | $38.00M | $57.00M | $53.00M | $61.00M | – | – |
| Other | – | – | – | – | – | – | – | – | – | – | $17.00M | $22.00M | – | – |
| Operating income | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $1.03B | $1.07B | $899.00M | $877.00M | $828.00M | $955.00M | $828.00M | $781.00M | $780.00M | -$220.00M | $1.09B | $1.12B | +24.8% |
| Neuroscience | $793.00M | $879.00M | $737.00M | $740.00M | $713.00M | $858.00M | $762.00M | $725.00M | $687.00M | -$31.00M | $994.00M | $929.00M | +11.2% |
| Medical Surgical | $485.00M | $605.00M | $499.00M | $531.00M | $486.00M | $575.00M | $512.00M | $525.00M | $459.00M | -$139.00M | $812.00M | $795.00M | -0.2% |
| Other Operating Segments, Including Diabetes | $74.00M | – | – | – | $37.00M | – | – | – | – | – | – | – | +100.0% |
| Diabetes | – | – | $57.00M | $53.00M | $26.00M | $383.00M | $50.00M | $33.00M | $24.00M | $90.00M | $118.00M | $101.00M | – |
| Other Segment | – | – | – | – | – | $10.00M | $13.00M | $12.00M | $13.00M | $2.00M | $7.00M | $4.00M | – |
| Other Operating Segments | – | – | -$1.00M | $9.00M | $11.00M | – | $13.00M | $12.00M | $13.00M | – | – | – | – |
By product or service
By region
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total other countries, excluding Ireland | $9.72B | $9.77B | $8.98B | $8.93B | $8.55B | $8.90B | $8.26B | $8.37B | $7.89B | $8.56B | $8.06B | $7.96B | 99.6% | +13.7% |
| United States | $4.91B | $4.87B | $4.49B | $4.52B | $4.22B | $4.55B | $4.24B | $4.30B | $4.08B | $4.34B | $4.12B | $4.18B | 50.3% | +16.1% |
| International | $4.85B | $4.94B | $4.52B | $4.45B | $4.35B | $4.38B | $4.06B | $4.10B | $3.83B | – | – | – | 49.7% | +11.4% |
| Rest of world | $4.81B | $4.90B | $4.49B | $4.41B | $4.32B | $4.35B | $4.03B | $4.07B | $3.80B | $4.22B | $3.94B | $3.78B | 49.3% | +11.3% |
| Ireland | $40.00M | $39.00M | $36.00M | $35.00M | $33.00M | $30.00M | $28.00M | $29.00M | $30.00M | $27.00M | $27.00M | $29.00M | 0.4% | +21.2% |
| Non-U.S. Developed Markets | – | – | – | – | – | – | – | – | – | $2.67B | $2.47B | $2.37B | – | – |
| Emerging Markets | – | – | – | – | – | – | – | – | – | $1.57B | $1.50B | $1.44B | – | – |
| International | – | – | – | – | – | $4.38B | $4.06B | $4.10B | $3.83B | $4.25B | $3.97B | $3.81B | – | – |
| Rest of world | – | – | – | – | – | – | $4.03B | $4.07B | $3.80B | – | $3.94B | $3.78B | – | – |
From the segment and revenue-disaggregation notes of Medtronic's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.